Barclays PLC Ultragenyx Pharmaceutical Inc. Call Options Transaction History

Barclays PLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $5.39 Million - $7.43 Million	144,000 Added 480.0%	174,000 $7.15 Million
Q4 2023 Feb 15, 2024	BUY	$31.73 - $49.19 $951,900 - $1.48 Million	30,000 New	30,000 $1.44 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $1.97 Million - $3.42 Million	49,300 Added 7042.86%	50,000 $3.47 Million
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $43,086 - $54,090	600 Added 600.0%	700 $53,000
Q4 2017 Feb 14, 2018	BUY	$43.54 - $57.32 $4,354 - $5,732	100	100 $5,000

287

88.1M

505K

198K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.81B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.